Precigen, Inc. (NASDAQ:PGEN) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Precigen, Inc. (NASDAQ:PGEN) have been assigned a consensus rating of “Moderate Buy” from the five analysts that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $7.00.

Separately, HC Wainwright restated a “buy” rating and issued a $4.00 price target on shares of Precigen in a report on Friday, November 15th.

Precigen Price Performance

Shares of PGEN stock opened at $0.79 on Thursday. The stock’s 50-day moving average is $0.84 and its 200 day moving average is $1.12. Precigen has a 1-year low of $0.65 and a 1-year high of $1.93. The company has a market cap of $229.96 million, a P/E ratio of -1.43 and a beta of 1.71.

Institutional Investors Weigh In On Precigen

Institutional investors have recently added to or reduced their stakes in the business. Iridian Asset Management LLC CT raised its position in shares of Precigen by 82.5% in the 3rd quarter. Iridian Asset Management LLC CT now owns 3,775,960 shares of the biotechnology company’s stock valued at $3,576,000 after purchasing an additional 1,706,815 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Precigen by 4.8% in the third quarter. Geode Capital Management LLC now owns 3,246,508 shares of the biotechnology company’s stock worth $3,075,000 after buying an additional 149,829 shares during the last quarter. State Street Corp lifted its stake in shares of Precigen by 1.0% during the third quarter. State Street Corp now owns 2,872,064 shares of the biotechnology company’s stock worth $2,720,000 after buying an additional 29,253 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Precigen by 11.6% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,222,850 shares of the biotechnology company’s stock valued at $1,158,000 after buying an additional 127,467 shares during the last quarter. Finally, Renaissance Technologies LLC increased its position in shares of Precigen by 12.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,182,690 shares of the biotechnology company’s stock valued at $1,869,000 after acquiring an additional 130,500 shares during the period. Institutional investors and hedge funds own 33.51% of the company’s stock.

About Precigen

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.